| INTRAVITREAL TISSUE PLASMINOGEN ACTIVATOR, PERFLUOROPROPANE (C3F8), AND RANIBIZUMAB OR PHOTODYNAMIC THERAPY FOR SUBMACULAR HEMORRHAGE SECONDARY TO WET AGE-RELATED MACULAR DEGENERATION. | |
| | |
MedLine Citation:
|
PMID: 23400079 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
PURPOSE:: To report a combined intravitreal treatment for submacular hemorrhage. METHODS:: This retrospective, noncomparative, interventional case series included 7 patients with neovascular age-related macular degeneration and 2 with idiopathic polypoidal choroidal vasculopathy, presenting with fovea-involving submacular hemorrhage ≥ 4 disk areas in size, of <10 days of duration. All patients received a single 0.05-mL intravitreal injection of 50 μg alteplase, 0.3 mL of 100% C3F8, and facedown positioning for 1 week. Patients with newly diagnosed age-related macular degeneration received 3 consecutive monthly intravitreal injections of 0.5 mg ranibizumab, followed by monthly retreatment as needed. Those with idiopathic polypoidal choroidal vasculopathy were treated with photodynamic therapy. RESULTS:: Mean (±SD) logarithm of the minimum angle of resolution visual acuity improved from 0.75 ± 0.35 at presentation to 0.35 ± 0.30 at a mean final follow-up of 15.1 months (P = 0.0078). Median Snellen acuity improved from 20/200 to 20/32. Visual acuity was stable in one case and improved in eight. The average size of submacular hemorrhage was 6.8 disk areas at presentation, reducing to 2.6 within 1 month (P = 0.0039). Subfoveal hemorrhage was displaced in all cases within 9 weeks. The mean pretreatment central retinal thickness of 669 μm reduced to 528 μm (P = 0.0039). One case developed transiently elevated intraocular pressure. Two developed breakthrough vitreous hemorrhage. No adverse events were attributed to tissue plasminogen activator. CONCLUSION:: Tissue plasminogen activator and C3F8, combined with intravitreal ranibizumab or photodynamic therapy, may result in anatomical clearance of submacular hemorrhage and improved visual acuity, in a condition with an otherwise poor visual prognosis. |
| | |
Authors:
|
Evangelia Papavasileiou; David H W Steel; Efstathios Liazos; Dominic McHugh; Timothy L Jackson |
Related Documents
:
|
1833839 - Effect of graft material on loss of erythrocytes after aortic operations. 23580739 - Effect of adequate single-drug versus combination antimicrobial therapy on mortality in... 16160689 - Infrainguinal eptfe vascular graft with bioactive surface heparin bonding. first clinic... 23378159 - Is abandonment of nonoperative management of hypertrophic pyloric stenosis warranted? 8899269 - Factors influencing graft clarity. 10388429 - Primary alveolar cleft bone grafting in unilateral cleft lip and palate: craniofacial f... 15674919 - Cardioprotective interventions for cancer patients receiving anthracyclines. 18606589 - Econazole-polycarbophil, a new delivery system for topical therapy: microbiological and... 19503009 - Partial ossicular replacement versus type ii tympanoplasty in congenital aural atresia ... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2013-2-7 |
Journal Detail:
|
Title: Retina (Philadelphia, Pa.) Volume: - ISSN: 1539-2864 ISO Abbreviation: Retina (Philadelphia, Pa.) Publication Date: 2013 Feb |
Date Detail:
|
Created Date: 2013-2-12 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8309919 Medline TA: Retina Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
*Department of Ophthalmology, King's College Hospital, London, United Kingdom †Sunderland Eye Infirmary, Sunderland, United Kingdom ‡School of Medicine, King's College London, London, United Kingdom. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: QUANTIFICATION OF CONTRAST RECOGNIZABILITY IN SEQUENTIAL EPIRETINAL MEMBRANE REMOVAL AND INTERNAL LI...
Next Document: THE PREVALENCE AND RISK FACTORS OF EPIRETINAL MEMBRANES: The Melbourne Collaborative Cohort Study.